Conference Call with Laurus Labs Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Laurus Labs announced Q2FY26 results Revenue: Rs 1,653 crore compared to Rs 1,224 crore during Q2FY25, up 35%. EBITDA: Rs 429 crore compared to Rs 182 crore during Q2FY25, up 136%. EBITDA Margin: 26.0% for Q2FY26. PBT: Rs 270 crore compared to Rs 23 crore during Q2FY25, up 1,074%. PAT: Rs 195 crore compared to Rs 20 crore during Q2FY25, up 875%. Satyanarayana Chava, Founder & Chief Executive Officer, said: “We continue to maintain leadership position in ARVs and make encouraging progress in delivering important clinical and commercial programs. Our Q2 reflects on-going expansion of CDMO business, supported by sustained growth in Generics. Earlier this quarter we announced land allocation from Andhra government and proposed investments to support future business expansion, augmenting our offerings across manufacturing scale and new technologies. We also made strategic investment of USD 2 million in Aarvik Therapeutics to have access to novel Antibody-drug conjugates (ADC) technology and pipeline aimed at accelerating our integrated ADC services. I have increasing confidence that our R&D; driven commercial strategy will continue to generate long-term value for our stakeholders.” V V Ravi Kumar, Executive Director & Chief Financial Officer, said: “Our strong Q2 performance was in line with expectations. We are pleased to report that fundamentals of our business remain strong, with sustained growth momentum in CDMO and Generic business. We have achieved revenues of Rs 1,653 crore, representing 35% growth and EBITDA of Rs 429 crore, representing 136% growth. The EBITDA margins continue to remain very healthy at 26.0%, supported by continuing operating leverage. Overall, we reported strong H1 performance. We achieved Rs 3,223 crore in revenues, representing 33% growth and EBITDA of Rs 818 crore, representing 132% growth, resulting in 25.4% EBITDA margins marking over 10% pts improvement over last year. Gross margins improved by over 4.5% pts to 59.6% due to favorable CDMO mix and operational improvements. Net Debt leverage has decreased significantly over last year to 1.3x EBITDA despite continuing CAPEX investments. Going ahead, we retain our focus to invest behind high value CDMO/CMO business opportunities to drive near and long-term growth and returns for our shareholders.” Result PDF